Different problems demand different intelligence. PeptideIQ investigates the evidence. CrashIQ goes deeper into vehicle safety. CineMatch learns the person behind the preferences. Three specialised agents. One idea: Go deeper. Understand more. Build intelligence that matters. NeuralWorks - We build intelligent agents.

Follow if you want to get the scoop on real world impact post interstellar network upgrade. We are tracking and analysing days 30, 90 and beyond !

Something new is taking shape at NeuralWorks. A new home for everything we’re building. Coming soon.

Building..

Building...

One AgentForge capability we'd love to see from @VeWorldAI Custom API tools. Give agents controlled access to external APIs, endpoints, parameters and structured responses, with authentication where required, the possibilities expand dramatically. Research agents → live data Finance agents → market feeds On-chain agents → blockchain data Business agents → enterprise systems Agent → API → structured data → intelligence For NeuralWorks, this would be a massive unlock for agents like PrismIQ, including direct access to public APIs like VeChainThor, without relying on web pages or third-party dashboards. @VeWorldAI is this on the AgentForge roadmap? 👀

Did Interstellar actually change VeChain? NeuralWorks is tracking it. Before the fork, we captured a baseline across: • transactions & clauses • contract deployments • active contracts • VET staking • VTHO issuance & burn • validators • StarGate participation • new protocols & assets The first 7-day comparison is now in. But 7 days is noise, not a verdict. The real tests come at 30 and 90 days - enough time to see whether easier EVM compatibility translates into developers, applications and measurable on-chain activity. We’ll follow the data either way. Pre-fork → 7D → 30D → 90D No narrative first. Measure first. NeuralWorks - Follow us to stay in the know

37,000 AI scientists built a virtual biotech company. That’s the headline. Our intelligence agent, PrismIQ investigated what actually happened. 37,000+ AI agents. 55,000+ clinical trials. A cancer-drug story that changes when you follow the timeline. And one much bigger question: Did thousands of AI agents actually produce better scientific reasoning - or did Stanford demonstrate something else entirely? We followed the evidence. 🎬 Full investigation now live. #AI #AIAgents #PrismIQ #NeuralWorks #vechain #veworldai

37,000 AI agents. One headline worth investigating. PrismIQ followed the evidence. The investigation is almost complete. 🎬 Full video coming soon.

PeptideIQ doesn’t treat every question the same. Ask a straightforward peptide question → get a focused, evidence-aware answer. Ask for an Intelligence Profile → PeptideIQ shifts into deeper research: broader source coverage, evidence strength + state, human vs preclinical evidence, independent replication, research trajectory, source verification and stronger claim controls. Ask for a report → that intelligence is then structured into a generated document with citations, methodology and evidence metadata. The important part: Document generation isn’t the research engine. The investigation, verification and evidence assessment happen first. The document is the structured output. Same agent. Different depth. The right rules for the job. NeuralWorks → PeptideIQ Evidence-first peptide intelligence.

PeptideIQ just got harder to fool. A major evidence-integrity update is now live. PeptideIQ now distinguishes between: Evidence that isn’t there. Evidence that is there, but insufficient. And evidence that simply couldn’t be adequately verified. Failed retrieval ≠ evidence of absence. The update introduces source-coverage tracking, claim-level verification states, retrieval-aware confidence, stronger negative-claim controls, and upgraded Intelligence Profiles. We put it straight through regression testing on BPC-157. The result: when source coverage was incomplete, PeptideIQ exposed the limitation instead of silently converting it into certainty. That’s the standard we’re building at NeuralWorks. Evidence first. Uncertainty exposed. No manufactured confidence. PeptideIQ by NeuralWorks

37,000 AI scientists. 55,000+ clinical trials analysed. A virtual biotech company. A cancer therapy strategy seemingly validated by Big Pharma. It sounds like a glimpse of autonomous science. So we gave the story to PrismIQ and told it to Follow the Signal. What it found changes the story considerably. The real breakthrough may not be 37,000 AI scientists at all. Full NeuralWorks investigation coming soon. #NeuralWorks #PrismIQ #AI #AIAgents

We’re going to start sharing more of what happens behind the scenes at NeuralWorks. What we’re building, what we’re testing, what fails, and what we learn along the way. Starting with something fundamental: We don’t want AI agents that just sound intelligent. We want agents that can be tested. Can they separate evidence from inference? Can they expose what they don’t know? Can they follow a signal beyond the obvious conclusion? Can they maintain quality when the question changes? That’s why we aggressively test and regression-test every NeuralWorks agent. The goal isn’t impressive answers. It’s intelligence you can interrogate. BUILDING NEURALWORKS // 01 #NeuralWorks #AIAgents

This is exactly the test CineMatch was built for. Not “people who watched this also watched…” Not genre matching. CineMatch builds your Cine DNA - learning why stories connect with you, then using those signals to predict what will connect next. Try both. The result is the interesting part.

👍🏼🎬